On profitability, gross margin in the fourth quarter was 70.9% (up 90 basis points year over year), while full-year gross margin was 70.6% (up 170 basis points). Wilson said the improvement reflected operational efficiencies in manufacturing, automation, and workflow optimization, along with scale benefits, partially offset by product mix.Wilson noted that “new store” growth—accounts open less than 12 months—represented approximately 68% of year-over-year volume growth. U.S. home enrollment for Zio Services ...

Core Insights - ICU Medical reported fourth-quarter 2025 revenue of $536 million, achieving 2% organic growth and 5% organic growth for the full year, with record performance in consumables and infusion systems [4][7] - The company delivered adjusted EBITDA of $98 million and adjusted earnings per share of $1.91, with gross margins remaining above 40% [3][7] - The 2026 outlook anticipates low- to mid-single-digit organic growth, adjusted EBITDA of $400–430 million, and adjusted EPS of $7.75–8.45, with a focus on improving free cash flow to reduce debt [5][15] Financial Performance - Adjusted SG&A expenses were reported at $113 million, and adjusted R&D expenses were $21 million, totaling adjusted operating expenses of $134 million, which is 25% of revenue [1] - The adjusted gross margin for the quarter was 40.5%, consistent with prior guidance of 40% to 41%, impacted by $11 million in tariff expenses [2][7] - Adjusted EBITDA declined 7% year-over-year from $106 million, primarily due to the deconsolidation of IV Solutions and tariff impacts, representing a $25 million EBITDA headwind [7] Business Segments - Consumables revenue grew 6% reported and 5% organic in Q4, with full-year growth of 7% reported and 6% organic, driven by strong demand in infusion consumables and oncology [8] - Infusion systems revenue increased 3% reported and 1% organic in Q4, with expectations of mid-single-digit organic growth in the near term [16] - Vital Care experienced a 6% organic decline and a 35% reported decline due to the IV Solutions deconsolidation, with management focusing on discontinuing loss-making SKUs [16] Regulatory and Integration Updates - The company closed a broad FDA warning letter related to Smiths Medical and completed major manufacturing and ERP integrations, which are expected to unlock synergies [6][11] - ICU Medical is pursuing 510(k) clearances for key products, including the Medfusion 5000 syringe pump and LifeShield software, as part of its strategy to enhance product offerings [10] 2026 Guidance and Strategic Focus - The company projects full-year adjusted gross margin of around 41%, with improvements expected throughout the year, despite manufacturing inflation and tariff expenses [14] - Free cash flow is expected to improve in 2026, with a focus on debt reduction and a long-term leverage target of 2x by early 2027 [18] - Management indicated that any strategic moves would need to avoid value destruction, particularly in the Critical Care segment, which is seen as less synergistic [19]

Core Viewpoint - Boston Scientific Corporation is under investigation for potential violations of federal securities laws following its fourth-quarter 2025 earnings report, which revealed a significant shortfall in its electrophysiology segment sales compared to market expectations [1][5]. Financial Performance - Boston Scientific reported fourth-quarter 2025 earnings, exceeding analyst expectations for earnings per share and total revenue, but its electrophysiology segment sales were $890 million, which was approximately $43 million below the consensus estimate of $933 million [2]. - The company had previously guided for organic growth of 11% to 13% for Q4 2025, but management indicated confidence in only about 15% growth going forward, creating a notable gap between market expectations and internal projections [4][5]. Market Dynamics - The electrophysiology market is one of the fastest-growing areas in cardiovascular medicine, with pulsed field ablation technology potentially replacing traditional thermal ablation procedures [3]. - Boston Scientific entered this market through the acquisition of Farapulse in 2021 and has made significant investments in expanding manufacturing capacity and physician training programs [3]. Growth Projections - The company projected that global penetration of pulsed field ablation technology would reach 50% by the end of 2025 and grow to approximately 80% by 2028 [3]. - The company emphasized strong growth rates in its electrophysiology segment, reporting 94% growth in Q2 2025 and 63% growth in Q3 2025 [4].

Record 2025 performance was primarily driven by the rapid adoption of iDose TR, which generated approximately $136 million in its first full year. Management attributes U.S. glaucoma growth to the successful advancement of the interventional treatment paradigm, shifting the standard of care toward earlier surgical intervention. International glaucoma net sales grew 13% on a constant currency basis in the fourth quarter, reflecting broad-based scaling of infrastructure despite emerging competitive tria ...

Core Viewpoint - ICU Medical reported a revenue of $535.94 million for the quarter ended December 2025, reflecting a 13.8% decline year-over-year, with an EPS of $1.91 compared to $2.11 in the same quarter last year [1] Financial Performance - The reported revenue of $535.94 million exceeded the Zacks Consensus Estimate of $528.97 million, resulting in a surprise of +1.32% [1] - The company achieved an EPS surprise of +13.52%, with the consensus EPS estimate being $1.68 [1] Key Metrics - Revenue from Infusion Systems was $176.3 million, slightly below the average estimate of $177.59 million from two analysts [4] - Revenue from Vital Care reached $79.7 million, surpassing the average estimate of $76.87 million from two analysts [4] - Revenue from Consumables was $284.7 million, exceeding the two-analyst average estimate of $280.64 million [4] Stock Performance - Shares of ICU Medical have returned -2.3% over the past month, compared to a -0.8% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - Tandem Diabetes Care, Inc. (TNDM) reported a revenue of $290.38 million for the quarter ended December 2025, reflecting a 15% increase year-over-year and a 5.21% surprise over the Zacks Consensus Estimate of $276 million. The EPS was -$0.01, significantly improved from -$0.44 in the same quarter last year, resulting in an EPS surprise of +80.51% [1] Financial Performance - The company’s pump shipments totaled 38,000, exceeding the average estimate of 35,032 by two analysts. In the U.S., pump shipments were 27,000, surpassing the average estimate of 25,632 [4] - Geographic sales in the U.S. reached $210.46 million, above the five-analyst average estimate of $203.09 million, but showed a year-over-year decline of -1.9%. Sales outside the U.S. were $79.92 million, significantly higher than the average estimate of $72.94 million, but represented a drastic year-over-year change of -99.9% [4] - Sales of pumps in the U.S. amounted to $111.49 million, exceeding the average estimate of $108.34 million, with a year-over-year increase of +13.3%. Sales outside the U.S. were $28.58 million, also above the average estimate of $26.16 million, reflecting a +10.9% year-over-year change [4] - Revenue from supplies and other in the U.S. was $98.98 million, surpassing the average estimate of $94.74 million, with a year-over-year increase of +15.2%. Outside the U.S., revenue was $51.34 million, exceeding the average estimate of $46.8 million, showing a +21.3% year-over-year change [4] Stock Performance - Shares of Tandem Diabetes Care have returned -8.7% over the past month, compared to a -0.8% change in the Zacks S&P 500 composite. The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

ICU Medical (NasdaqGS:ICUI) Q4 2025 Earnings call February 19, 2026 04:30 PM ET Company ParticipantsBrian Bonnell - CFOJayson Bedford - Managing Director of Medical TechnologyJohn Mills - Managing PartnerLarry Solow - PartnerVivek Jain - CEO and ChairmanConference Call ParticipantsBrett Fishbin - VP and Senior Equity Research AnalystJason Bednar - Senior Research AnalystMike Matson - Senior AnalystOperatorGood day, and welcome to the ICU Medical, Inc., fourth quarter 2025 earnings conference call. All parti ...

Pulse Biosciences (NasdaqCM:PLSE) Q4 2025 Earnings call February 19, 2026 04:30 PM ET Company ParticipantsAnthony Petrone - Managing Director Equity ResearchJon Skinner - CFOPaul LaViolette - Co-Chair and CEORobert Duggan - Co-ChairTrip Taylor - Principal of Investor RelationsNone - ShareholderConference Call ParticipantsJosh Jennings - Managing Director and Senior AnalystSuraj Kalia - Managing Director and Senior AnalystOperatorLadies and gentlemen, thank you for standing by. My name is Colby, and I'll be ...

Pulse Biosciences (NasdaqCM:PLSE) Q4 2025 Earnings call February 19, 2026 04:30 PM ET Company ParticipantsAnthony Petrone - Managing Director Equity ResearchJon Skinner - CFOPaul LaViolette - Co-Chair and CEORobert Duggan - Co-ChairTrip Taylor - Principal of Investor RelationsNone - ShareholderConference Call ParticipantsJosh Jennings - Managing Director and Senior AnalystSuraj Kalia - Managing Director and Senior AnalystOperatorLadies and gentlemen, thank you for standing by. My name is Colby, and I'll be ...

Financial Data and Key Metrics Changes - iRhythm reported Q4 2025 revenue of $208.9 million, representing a 27.1% year-over-year growth, and full year 2025 revenue of $747.1 million, reflecting a 26.2% growth compared to 2024 [19][20] - Gross margin for Q4 was 70.9%, an increase of 90 basis points year-over-year, while full year gross margin was 70.6%, an improvement of 170 basis points year-over-year [21] - The company achieved its first positive net income in Q4 2025, amounting to $5.6 million, or $0.17 per diluted share, while the full year net loss was $44.6 million, or a loss of $1.39 per diluted share [22] - Adjusted EBITDA for Q4 was $34.3 million, or 16.4% of revenue, marking a 470 basis point improvement year-over-year, and full year adjusted EBITDA was $68.9 million, or 9.2% of revenue, representing an improvement of over 1,000 basis points compared to 2024 [23][24] Business Line Data and Key Metrics Changes - The growth in Q4 was driven by sustained volume demand across all channels, with new store growth accounting for approximately 68% of year-over-year volume growth [20] - The Zio AT offering performed exceptionally well, with unit growth running more than twice the company average for the year [12][14] - The company serves approximately 40,000 primary care physicians, with more than one-third of volume originating in primary care settings [9] Market Data and Key Metrics Changes - iRhythm holds a 72% market share in long-term continuous monitoring, with the segment growing in the high teens [7] - International markets represent a significant growth opportunity, with the company now commercial in the U.K., select E.U. markets, and Japan, where it holds less than 1% market share [14][15] - The U.K. delivered the largest quarter of volume ever for iRhythm, and the company is participating in pilots under the NHS Supply Chain's value-based procurement program [14] Company Strategy and Development Direction - The company aims to shift from episodic detection to proactive, integrated, and increasingly predictive care, addressing the need for long-term continuous monitoring [8] - iRhythm's strategy includes expanding margins through operational efficiencies, advancing platform innovation, and scaling international and adjacent markets [16] - The company is focused on delivering durable, volume-led growth across cardiology, primary care, and innovative channels while maintaining operational excellence [16][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver another year of durable, volume-led growth while expanding profitability [29] - The company is well-positioned to lead market expansion, driven by trends such as an aging population and increasing prevalence of arrhythmias [15][16] - Management highlighted the importance of confirmatory diagnoses in the context of recent regulatory scrutiny and expressed optimism about the potential tailwinds from these changes [17][41] Other Important Information - 2026 marks iRhythm's twentieth anniversary, with a goal to become a billion-dollar company by 2027 [18] - The company expects revenue for full year 2026 to be in the range of $870 million-$880 million, representing 16%-18% year-over-year growth [24][25] Q&A Session Summary Question: Concerns about the elimination of chart-derived diagnosis from CMS - Management addressed concerns by emphasizing that Zio provides confirmatory diagnoses, which is crucial for compliance and documentation [32][34] Question: Guidance on gross and operating margins for 2026 - Management provided guidance for adjusted EBITDA margin of 11.5%-12.5% for 2026 and expected gross margin improvement of 80-100 basis points relative to 2025 [37] Question: Potential tailwind from CMS proposals regarding chart scraping - Management indicated that the confirmatory diagnosis aspect of Zio could serve as a tailwind, although no specific assumptions were factored into forward-looking expectations [40][41] Question: AI concerns and potential impact on billing - Management expressed confidence in their unique data and regulatory position, stating that their platform's closed nature and established workflows would mitigate risks associated with AI adoption [48][49] Question: Updates on MCT product timeline and features - Management confirmed that the next-generation MCT device is expected to launch in the first half of 2027, featuring a mobile gateway and enhanced algorithms [56][57] Question: Guidance on international growth for 2026 - Management indicated that international growth is expected to slightly outpace overall company growth, with significant potential in newly opened markets [43]